Medical Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer TherapiesBy Marie JonesJune 2, 2022 Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies…
